0001192482-15-000166.txt : 20150506 0001192482-15-000166.hdr.sgml : 20150506 20150506161505 ACCESSION NUMBER: 0001192482-15-000166 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150506 FILED AS OF DATE: 20150506 DATE AS OF CHANGE: 20150506 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fleming Alison B CENTRAL INDEX KEY: 0001640701 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 15837156 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2015-05-06 0 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001640701 Fleming Alison B 780 DEDHAM STREET, SUITE 800 CANTON MA 02021 0 1 0 0 Vice President, Product Devlp Stock Option (right to purchase) 3.38 2015-11-01 Common Stock 1086 D Stock Option (right to purchase) 3.38 2016-12-01 Common Stock 1086 D Stock Option (right to purchase) 3.38 2017-11-01 Common Stock 1811 D Stock Option (right to purchase) .90 2019-04-23 Common Stock 1811 D Stock Option (right to purchase) .90 2020-02-26 Common Stock 1811 D Stock Option (right to purchase) 3.31 2021-02-08 Common Stock 1449 D Stock Option (right to purchase) .48 2022-05-10 Common Stock 7246 D Stock Option (right to purchase) .48 2023-01-30 Common Stock 12681 D Stock Option (right to purchase) .28 2024-03-05 Common Stock 15623 D Stock Option (right to purchase) .28 2024-03-05 Common Stock 14492 D Stock Option (right to purchase) 5.73 2025-03-19 Common Stock 60379 D All 1,086 options are exercisable. All 1,086 options are exercisable. All 1,811 options are exercisable. All 1,811 options are exercisable. All 1,811 options are exercisable. All 1,449 options are exercisable. 5,585 options are exercisable. The options vest and become exercisable over a 4-year period commencing on April 1, 2012. Twenty-five percent (25%) of the options vested and became exercisable on April 1, 2013 and then in equal monthly installments (rounded up to the nearest whole option) at the end of each monthly period over the remaining three years of the 4-year period. 7,397 options are exercisable. The options vest and become exercisable in equal installments (rounded up to the nearest whole option) at the end of each month over a 4-year period commencing on January 24, 2013. 4,557 options are exercisable. The options vest and become exercisable in equal installments (rounded up to the nearest whole option) on a monthly basis over a 4-year period commencing on March 5, 2014. 4,227 options are exercisable. The options vest and become exercisable over a 4-year period commencing on March 5, 2014. Twenty-five percent (25%) of the options vested and became exercisable on March 5, 2015 and then in equal monthly installments (rounded up to the nearest whole option) at the end of each monthly period over the remaining three years of the 4-year period. 1,258 options are exercisable. The options vest and become exercisable in equal installments (rounded up to the nearest whole option) on a monthly basis over a 4-year period commencing on March 19, 2015. /s/ Paul Brannelly as Attorney-In-Fact For Alison B. Fleming 2015-05-06 EX-24 2 poafleming.htm POA

                                POWER OF ATTORNEY



 Know all by these presents, that the undersigned hereby constitutes

and appoints each of Paul Brannelly and Michael T. Heffernan, with full power

to act singly, as the undersigned's true and lawful attorney-in-fact with full

power of substitution to:



 (1)  execute for and on behalf of the undersigned, in the

undersigned's capacity as an officer and/or director and/or beneficial owner

of Collegium Pharmaceutical Inc.  (the "Company"), Form ID Application,

Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act

of 1934, as amended and the rules thereunder;



 (2)  do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and execute

any such Form ID Application, Forms 3, 4 or 5, complete and execute any

amendment or amendments thereto and timely file such forms with the

United States Securities and Exchange Commission and any stock exchange

or similar authority; and



 (3)  take any other action of any type whatsoever in connection

with the foregoing which, in the opinion of such attorney-in-fact, may be of

benefit to, in the best interest of, or legally required by, the undersigned,

it being understood that the documents executed by such attorney-in-fact

on behalf of the undersigned pursuant to this Power of Attorney shall be in

such form and shall contain such terms and conditions as such attorney-in-fact

may approve in such attorney-in-fact's discretion.



 The undersigned hereby grants to the attorney-in-fact full power and

authority to do and perform any and every act and thing whatsoever requisite,

necessary or proper to be done in the exercise of any of the rights and powers

herein granted, as fully to all intents and purposes as the undersigned might

or could do if personally present, with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact, or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be

done by virtue of this power of attorney and the rights and powers herein

granted.



 This power of attorney shall remain in full force and effect until

revoked by the undersigned in a signed writing delivered to the attorney-in-fact.



 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney

to be executed as of the 24th day of April, 2015.







     /s/Alison B. Fleming, Ph.D.

     Name: Alison B. Fleming, Ph.D.

                                        Title: VP, Product Development